Secondary progressive multiple sclerosis (SPMS)

Active Ingredient: Tolebrutinib

Indication for Tolebrutinib

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Tolebrutinib is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.

For this indication, competent medicine agencies globally authorize below treatments:

60 mg once daily

For:

Dosage regimens

Oral, 60 milligrams tolebrutinib, once daily to meals.

Detailed description

The recommended dose is 60 mg orally once daily with a meal. Liver monitoring should be performed before and during treatment.

Dose modifications for aminotransferase elevations

The following table summarises recommendations for dose adjustment and monitoring for patients who develop elevated transaminases during therapy.

Therapy modifications and monitoring for elevated transaminases:

Laboratory abnormalitiesTherapy modifications
• ALT or AST > 3 x and
≤ 5 x ULN† with clinical
symptoms OR with
concurrent total bilirubin
> 2x ULN

• ALT or AST > 5 x ULN
• Withhold treatment.
• Repeat labs every 2-3 days until ALT or AST down-trending and
monitor weekly until ALT or AST less than 1.5 x ULN.
• Investigate to identify probable causes.
If an alternative cause other than drug-induced liver injury (DILI) is
identified, reinitiation of treatment can be considered when ALT or
AST decreases to less than 1.5 x ULN. Upon reinitiation of treatment,
if ALT or AST greater than 3 x ULN, permanently discontinue
treatment.
If no alternative cause to DILI is identified:
• Permanently discontinue treatment if any of the following occurred
as the initial event:
o ALT or AST greater than 8 x ULN
o ALT or AST greater than 5 x ULN for greater than
2 weeks
o ALT or AST greater than 3 x ULN and total bilirubin
greater than 2 x ULN
• If the above criteria are not met, continue treatment as clinically
indicated.

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal
Fatigue, nausea, vomiting, abdominal pain or tenderness, fever, rash, anorexia, jaundice, and/or eosinophilia

Missed dose

If a dose is missed on the intended time of day, take the dose as soon as possible on the same day. Do not double the dose the next day to make up for a missed dose.

Dosage considerations

It must be taken with a meal preferably at the same time each day.

Active ingredient

Tolebrutinib

Η τολεμπρουτινίμπη είναι κυρίως αναστολέας της τυροσινικής κινάσης του Bruton (BTK). Παρόλο που ο ακριβής μηχανισμός με τον οποίο η τολεμπρουτινίμπη ασκεί τη θεραπευτική δράση της στην ΠΣ δεν είναι πλήρως κατανοητός, υπάρχουν στοιχεία που υποστηρίζουν ότι αναστέλλει την ενεργοποίηση των Β κυττάρων, των μακροφάγων και της μικρογλοίας στην περιφέρεια και στο ΚΝΣ.

Read more about Tolebrutinib

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.